Trial Profile
A 4-day, Open-Label, Multicenter Phase 3b Study of IV YM087 in Patients With Euvolemic or Hypervolemic Hyponatremia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Jan 2019
Price :
$35
*
At a glance
- Drugs Conivaptan (Primary)
- Indications Hyponatraemia
- Focus Therapeutic Use
- Sponsors Cumberland Pharmaceuticals
- 10 Feb 2016 Results published in the Cumberland Pharmaceuticals Media Release.
- 01 Jul 2014 New trial record